September 6, 2019
CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. CRISPR-Cas9 is a system found in bacteria that helps with immune defence. Like a tiny pair of molecular scissors, the Cas9 component allows scientists to precisely cut away flawed parts of genes.
The Broad Institute of MIT and Harvard (“Broad”) and MilliporeSigma, the life-sciences tools division of German pharmaceutical giant Merck KGaA (“Merck”), have agreed to a framework through which they will grant researchers nonexclusive rights to patents held by both organizations with a single licence. Non-profit and academic institutions will be permitted to license the patents for free while others will have to pay a fee.
According to MilliporeSigma CEO Udit Batra, the Broad-Merck partnership aims to simplify the path to licensing CRISPR technology, which will “make it more widely available to the global research and discovery community” and “make it easier for … customers to be successful in their research that shortens drug development timelines for previously untreatable diseases.”
Author: Larissa Fulop